The SCOTUS Antibody Ruling Has an Uncertain Impact for Drug Makers and Patients
Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.

Scholars, analysts, and companies cannot agree on what Amgen v. Sanofi means for patients, drug makers, and innovation.
SCOTUS revisits enablement, but Amgen v. Sanofi probably won’t transform patent law on its own.